Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Eli Lilly & Co.
LLYHealthcareGenerated Aug 19, 2026, 10:31 PM UTC
LLY (Eli Lilly & Co.) analytical snapshot. Revenue grew +44.7% YoY to $65.18B. 5-year revenue CAGR +18.1%; 10y CAGR +13.3%. Net margin at 31.67% (expanding ▲). Market cap $1.21T at $1280.34 per share. Trailing P/E 55.79, P/S 18.49, P/B 35.58. Graham number $136.32 (trades above intrinsic). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 17 (data confidence 74%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed Aug 5, 2026. 5 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 12, 2026.
- Latest quarterly report (10-Q) filed Aug 5, 2026.
- 5 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Eli Lilly & Co.; broad institutional reporting.
- Recent filers include PROVIDENT ADVISORS LLC, INTRUST BANK NA, PROVIDENT INVESTMENT ADVISORS INC.
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| PROVIDENT ADVISORS LLC | 13F-HR | Aug 13, 2004 |
| INTRUST BANK NA | 13F-HR | Feb 7, 2001 |
| PROVIDENT INVESTMENT ADVISORS INC | 13F-HR | Apr 27, 2001 |
| PROVIDENT INVESTMENT ADVISORS INC | 13F-HR | Apr 15, 2003 |
| PROVIDENT INVESTMENT ADVISORS INC | 13F-HR | Jul 16, 2003 |
| Date | Form | Description |
|---|---|---|
| Aug 5, 2026 | 8-K | 8-K |
| May 20, 2026 | 8-K | 8-K |
| May 7, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Feb 4, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
3 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. Revenue grew +44.7% but receivables grew +61.4% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- Receivables outpacing revenue: Accounts receivable grew +61.4% YoY vs revenue growth of +44.7%. The +16.7% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Inventory buildup exceeds sales growth: Inventory grew +81.1% vs revenue +44.7%. Excess inventory may signal weakening demand, potential write-downs, or supply chain overcommitment. Watch gross margin for discounting impact.
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 3 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- R&D intensity declining: R&D as % of revenue fell from 15.6% to 11.0%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- Endogenous analysis: Revenue grew +44.7% but receivables grew +61.4% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Ongoing high-severity risk language: Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $45.04B | $65.18B | $20.14B | +44.7% |
| Net income | $10.59B | $20.64B | $10.05B | +94.9% |
| Operating cash flow | $8.82B | $16.81B | $8.00B | +90.7% |
| Total assets | $78.71B | $112.48B | $33.76B | +42.9% |
| Long-term debt | $29.47B | $40.87B | $11.39B | +38.7% |
| Cash & equivalents | $3.27B | $7.27B | $4.00B | +122.4% |
| Stockholders equity | $14.19B | $26.54B | $12.34B | +87.0% |
| Inventory | $7.59B | $13.74B | $6.15B | +81.1% |
| Accounts receivable | $11.01B | $17.76B | $6.75B | +61.4% |
| R&D expense | $7.03B | $7.19B | $164.9M | +2.3% |
| SG&A expense | $8.59B | $11.09B | $2.50B | +29.1% |
| Interest expense | $331.6M | $485.9M | $154.3M | +46.5% |
| Type | Concepts |
|---|---|
| Removed | AdvertisingExpense, AllocatedShareBasedCompensationExpense, AllowanceForDoubtfulAccountsReceivableCurrent, AmortizationOfIntangibleAssets, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax, AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Restatement of financial statements | high | 3 | 1 | Ongoing |
| Impairment charge | medium | 5 | 4 | Ongoing |
| Restructuring | medium | 5 | 9 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
| Related party transactions | low | 1 | 0 | NEW |
Fundamentals
Revenue grew +44.7% YoY to $65.18B. 5-year revenue CAGR +18.1%; 10y CAGR +13.3%. Net margin at 31.67% (expanding ▲).
- Revenue grew +44.7% YoY to $65.18B.
- 5-year revenue CAGR +18.1%; 10y CAGR +13.3%.
- Net margin at 31.67% (expanding ▲).
- Return on equity 77.78%, ROA 18.35%, ROIC 0.00%.
- Gross margin 0.00%, operating margin 0.00%.
- Net income up ▲ +94.9% YoY.
- Debt/equity 0.87, current ratio 1.35, net debt $20.52B.
- Asset turnover 0.46 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $45.04B | +32.0% | 0.00 | 0.00 | 23.51 | — | 74.62 |
| 2025 | $65.18B | +44.7% | 0.00 | 0.00 | 31.67 | — | 77.78 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 30, 2024 | $11.44B | +20.4% | — | 8.48% |
| Mar 31, 2025 | $12.73B | +45.2% | +11.3% | 21.67% |
| Jun 30, 2025 | $15.56B | +37.6% | +22.2% | 36.39% |
| Sep 30, 2025 | $17.60B | +53.9% | +13.1% | 31.72% |
| Mar 31, 2026 | $19.80B | +55.5% | +12.5% | 37.36% |
| Jun 30, 2026 | $22.97B | +47.7% | +16.0% | 30.88% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $1.21T at $1280.34 per share. Trailing P/E 55.79, P/S 18.49, P/B 35.58. Graham number $136.32 (trades above intrinsic).
- Market cap $1.21T at $1280.34 per share.
Price & Technicals
Price $1280.34 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 68.97.
- Price $1280.34 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Moderate. Leverage debt/equity 0.87 (moderate). Liquidity current ratio 1.35 (adequate).
- Composite risk: Moderate.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 17
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Eli Lilly & Co. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+44.7%** YoY to $65.18B..
Peer comparison
Defensive groupHow LLY stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY● you | 17 | Neutral |
| Gilead Sciences GILD | 10 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Johnson & Johnson JNJ | 9 | Neutral |
| Intuitive Surgical Inc. ISRG | 9 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Merck & Co. MRK | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Zoetis Inc. ZTS | 0 | Neutral |
| Vertex Pharmaceuticals VRTX | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Illumina Inc. ILMN | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Costco Wholesale COST | -6 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Mondelez International MDLZ | -12 | Neutral |
| Kroger Co. KR | -13 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |